News & Blog

A growing range of voices—from different countries, disciplines, and political leanings—are raising questions about psychiatric drugs, deprescribing, and the systems that shape mental health care. Many of these questions will be familiar to anyone who has been following the conversation for years.

Here are five notable pieces from recent weeks.

This report presents findings from a national online survey of 1,260 U.S. adults with a history of SSRI prescription. The study  examines what side effect information respondents recalled receiving from prescribers, what information they would have preferred to receive, and the size of the gap between recalled education and patient preference.

Inner Compass Research Institutes issues a statement in response to the conversations among psychiatric communities.

Inner Compass Research Institute provides a statement in response to the "Dear Colleague" letter on psychiatric prescribing issued on May 4th, 2026.

Inner Compass Research Institute issues a statement about the May 4th Summit on Mental Health and Overmedicalization

A recent brief report from 

On May 4, 2026, I stood before colleagues, policymakers, clinicians, and advocates at the MAHA Institute’s Mental Health and Overmedicalization Summit in Washington, DC

On May 4th, Inner Compass Initiative had the opportunity to help coordinate and participate in the Menta

A new executive order (EO) is making headlines, “

Nature published